Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by Analysts

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has received an average rating of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $73.00.

A number of research firms have recently issued reports on APGE. Stifel Nicolaus lifted their price target on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a "buy" rating in a research report on Tuesday, March 5th. Wedbush reiterated an "outperform" rating and set a $87.00 price target on shares of Apogee Therapeutics in a research report on Monday, May 13th. Jefferies Financial Group lifted their price target on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Bank of America began coverage on shares of Apogee Therapeutics in a research report on Friday, May 10th. They set a "buy" rating and a $80.00 price target for the company. Finally, Guggenheim lifted their price target on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the company a "buy" rating in a research report on Tuesday, March 5th.

Apogee Therapeutics Stock Performance

NASDAQ:APGE traded down $0.05 during mid-day trading on Friday, reaching $38.00. The stock had a trading volume of 1,031,525 shares, compared to its average volume of 378,061. The firm has a market capitalization of $2.22 billion and a price-to-earnings ratio of -7.24. Apogee Therapeutics has a twelve month low of $14.19 and a twelve month high of $72.29. The business has a 50 day simple moving average of $47.41 and a 200 day simple moving average of $43.65.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.04). As a group, sell-side analysts expect that Apogee Therapeutics will post -2.64 earnings per share for the current year.

Institutional Trading of Apogee Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. EntryPoint Capital LLC grew its stake in shares of Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Apogee Therapeutics during the fourth quarter valued at about $155,000. SG Americas Securities LLC grew its stake in shares of Apogee Therapeutics by 34.0% during the fourth quarter. SG Americas Securities LLC now owns 6,607 shares of the company's stock valued at $185,000 after acquiring an additional 1,676 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Apogee Therapeutics during the first quarter valued at about $212,000. Finally, New York State Common Retirement Fund grew its stake in shares of Apogee Therapeutics by 113.3% during the fourth quarter. New York State Common Retirement Fund now owns 8,969 shares of the company's stock valued at $251,000 after acquiring an additional 4,764 shares in the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.